Mesenchymal stem cell therapy: Two steps forward, one step back

Trends in Molecular Medicine

Volumn 16, Issue 5, 2010, Pages 203-209

  Ankrum, James ^a   Karp, Jeffrey M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; STEROID;

ACUTE HEART INFARCTION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CELL DIFFERENTIATION; CELL FATE; CELL HOMING; CELL VIABILITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HEART FAILURE; HUMAN; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PATIENT SAFETY; SYSTEMIC THERAPY; THERAPY EFFECT; ANIMAL; CYTOLOGY; MESENCHYMAL STROMA CELL; PHYSIOLOGY;

ANIMALS; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MESENCHYMAL STROMAL CELLS;

EID: 77952319188     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.02.005     Document Type: Article

References (55)

1. Phinney D.G., and Prockop D.J. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair - current views. Stem Cells 25 (2007) 2896-2902
2. Karp J.M., and Leng Teo G.S. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4 (2009) 206-216
3. Iso Y., et al. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem. Biophys. Res. Commun. 354 (2007) 700-706
4. Lee R.H., et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5 (2009) 54-63
5. Ortiz L.A., et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 11002-11007
6. Tögel F., et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am. J. Physiol. Renal Physiol. 292 (2007) F1626-F1635
7. van Poll D., et al. Mesenchymal stem cell therapy for protection and repair of injured vital organs. Cell. Mol. Bioeng. 1 1 (2008) 42-50 doi:10.1007/s12195-008-0001-2
8. van Hennik P.B., et al. Seeding efficiency of primitive human hematopoietic cells in nonobese diabetic/severe combined immune deficiency mice: implications for stem cell frequency assessment. Blood 94 (1999) 3055-3061
9. Cui J., et al. Bone marrow cell trafficking following intravenous administration. Br. J. Haematol. 107 (1999) 895-902
10. Di Nicola M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99 (2002) 3838-3843
11. Krampera M., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101 (2003) 3722-3729
12. Laflamme M., and Murry C. Regenerating the heart. Nat. Biotechnol. 23 (2005) 845-856
13. Mangi A.A., et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat. Med. 9 (2003) 1195-1201
14. Schuleri K., et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur. Heart J. 30 (2009) 2722-2732
15. Hare J.M., et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J. Am. Coll. Cardiol. 54 (2009) 2277-2286
16. Meyer G.P., et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113 (2006) 1287-1294
17. Le Blanc K., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371 (2008) 1579-1586
18. Mills, C.R. (2009) Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III GvHD Trials. (Press Release) (cited 1 November, 2009); available from: http://investor.osiris.com/releasedetail.cfm?ReleaseID=407404
19. Mills, C.R. (2009) Osiris Therapeutics Reports Interim Data for COPD Stem Cell Study. (Press Release) (cited 1 November, 2009); available from: http://investor.osiris.com/releasedetail.cfm?ReleaseID=391580
20. Schrepfer S., et al. Stem cell transplantation: the lung barrier. Transplant Proc. 39 (2007) 573-576
21. Sackstein R., et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat. Med. 14 (2008) 181-187
22. Gao J., et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs (Print) 169 (2001) 12-20
23. Barbash I.M., et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 108 (2003) 863-868
24. Toma C., et al. Fate of culture-expanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics. Circ. Res. 104 (2009) 398-402
25. Le Blanc K., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
26. Giordano A., et al. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J. Cell. Physiol. 211 (2007) 27-35
27. Chen S.L., et al. Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin. Med. J. 117 (2004) 1443-1448
28. NIH (2008) Evaluation of PROCHYMAL (Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease. 27 June, 2008 (cited 29 June, 2008); available from: http://clinicaltrials.gov/ct2/show/NCT00482092?term=osiris&rank=3
29. Smits P.A., et al. Distribution of circulation-derived endothelial progenitors following systemic delivery. Endothelium 14 (2007) 1-5
30. Rombouts W.J., and Ploemacher R.E. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 17 (2003) 160-170
31. Kraitchman D. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 112 (2005) 1451-1461
32. Pittenger M.F., and Martin B.J. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ. Res. 95 (2004) 9-20
33. Lo Celso C., et al. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature 457 (2009) 92-96
34. Sipkins D.A., et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 435 (2005) 969-973
35. Wang H., et al. Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells 27 (2009) 1548-1558
36. Spaeth E., et al. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 15 (2008) 730-738
37. Wagner J., et al. Optimizing mesenchymal stem cell-based therapeutics. Curr. Opin. Biotechnol. 20 5 (2009) 531-536
38. Quevedo H.C., et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 14022-14027
39. Nauta A.J., and Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 110 (2007) 3499-3506
40. Németh K., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15 (2009) 42-49
41. Lee R.H., et al. The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood 113 (2009) 816-826
42. Friedenstein A., et al. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp. Hematol. 4 5 (1976) 267-274
43. Caplan A.I. Why are MSCs therapeutic? New data: new insight. J. Pathol. 217 (2009) 318-324
44. Dominici M., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8 (2006) 315-317
45. Bianco P., et al. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2 (2008) 313-319
46. Prockop D. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol. Ther. 17 6 (2009) 939-946
47. da Silva Meirelles L., and Chagastelles P. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J. Cell Sci. 119 11 (2006) 2204-2213
48. Burchfield J.S., and Dimmeler S. Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair 1 1 (2008) 1-11
49. Rüster B., et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 108 (2006) 3938-3944
50. Runnels J.M., et al. Imaging molecular expression on vascular endothelial cells by in vivo immunofluorescence microscopy. Mol. Imaging 5 (2006) 31-40
51. Kidd S., et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescence imaging. Stem Cells 27 10 (2009) 2614-2623
52. Kraitchman D.L., et al. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 107 (2003) 2290-2293
53. Milner C.M., et al. TSG-6: a pluripotent inflammatory mediator?. Biochem. Soc. Trans. 34 (2006) 446-450
54. Lee T.H., et al. A novel secretory tumor necrosis factor-inducible protein (TSG-6) is a member of the family of hyaluronate binding proteins, closely related to the adhesion receptor CD44. J. Cell Biol. 116 (1992) 545-557
55. Shah B.S., et al. Labeling of mesenchymal stem cells by bioconjugated quantum dots. Nano Letters 7 10 (2007) 3071-3079